Sorafenib for the Treatment of Advanced Renal Cell CarcinomaRobert C. Kane, Richard Pazdur, Chengyi Liang et al.|Clinical Cancer Research|2006Cited by 466
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic LeukemiaR. Angelo de Claro, Richard Pazdur, Karen M. McGinn et al.|Clinical Cancer Research|2015Cited by 165
FDA Approval Summary: Vorasidenib for <i>IDH</i> -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following SurgeryMichael I. Barbato, Nicole Drezner, Amy Barone et al.|Clinical Cancer Research|2025Cited by 9